Clinical trials: SARS-COV2 Virus
COVID-19
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
- Trial name
- NCT07089706
- Testing
- mRNA-1283.251 Variant-containing Formulation
- Where
- 5 sites in United States
- Volunteers
- 832 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV2 Infection (COVID-19), URTI - Viral Upper Respiratory Tract Infection
Seawater Nasal Wash to Relieve COVID-19 Nasal Symptoms and Reduce SARS-CoV-2 Viral Load.
Prospective, randomized, controlled, multicenter, parallel clinical trial to assess the efficacy of seawater nasal wash to relieve COVID-19 and URTIs nasal symptoms and reduce intranasal viral load in subjects with mild to…
- Trial name
- SeaCare (NCT04916639)
- Testing
- Device: Physiomer undiluted seawater nasal spray
- Where
- France
- Volunteers
- 370 people
- Sponsor
- Laboratoire de la Mer
COVID-19
PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19
This is a phase 2 double-blind, randomized study of PBI-0451(Pomotrelvir) in nonhospitalized symptomatic adults with COVID-19. PBI-0451(Pomotrelvir) is a new chemical entity and inhibitor of the main protease of coronaviruses…
- Trial name
- NCT05543707
- Testing
- PBI-0451 (Pomotrelvir)
- Where
- 54 sites in United States
- Volunteers
- 242 people
- Sponsor
- Pardes Biosciences, Inc.
Corona Virus Infection
BBV152/BBV154 Heterologus Prime-Boost Study
All participants will be assessed for immunogenicity and safety endpoints and provide a blood sample before the administration of the first dose of IP.
- Trial name
- BBV152BBV154 (NCT05639998)
- Testing
- COVAXIN(BBV152), BBV154 Intranasal Vaccine
- Where
- 11 sites in India
- Volunteers
- 608 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
COVID-19
Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older
This is a Phase III, randomized, placebo-controlled, observer-blinded, parallel-group, multi-center study to assess the safety, reactogenicity, and immunogenicity of heterologous booster vaccination of SK SARS-CoV-2 recombinant…
- Trial name
- NCT05501522
- Testing
- GBP510 adjuvanted with AS03
- Where
- 4 sites in Colombia, Nepal
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
COVID-19
Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase 1\&2 clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Life Sciences Co. , Ltd.
- Trial name
- NCT04383574
- Testing
- Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28, Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
- Where
- China
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Coronavirus Infections
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and…
- Trial name
- COVID-19 (NCT04414618)
- Testing
- Opaganib
- Where
- 9 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- RedHill Biopharma Limited
SARS-CoV-2 Infection
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006）in healthy participants aged 18 or more.
- Trial name
- NCT05439824
- Testing
- SYS6006 20 μg, SYS6006 30 μg
- Where
- 2 sites in China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
COVID-19, Corona Virus Infection
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
Agent Name and Study Duration ArtemiC is a medical spray comprised of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (=Boswellia) (15 mg/ml) and vitamin C (60 mg/ml) in micellar formulation for spray administration.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2, Coronavirus
- Trial name
- NCT04382040
- Testing
- ArtemiC
- Where
- 4 sites in India, Israel
- Volunteers
- 50 people
- Sponsor
- MGC Pharmaceuticals d.o.o
COVID-19
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19
AD17002 has demonstrated superior safety and efficacy as a nasal adjuvant function to an influenza vaccine in two completed clinical studies, and has innate immune modulatory and anti-inflammatory properties which could…
- Trial name
- NCT05069610
- Testing
- AD17002
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Advagene Biopharma Co. Ltd.
COVID, Covid-19
Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19
Corona virus disease 2019 (COVID-19) is caused by SARS-CoV-2, a plus-sense single-stranded RNA virus. After an incubation period, which typically lasts for 5-6 days, COVID-19 patients present with a mild illness that lasts for a…
- Trial name
- NCT04465513
- Testing
- Best Standard of Care + CARDIO, Best Standard of Care
- Where
- 8 sites in Brazil, Canada and 3 more
- Volunteers
- 14 people
- Sponsor
- Hofseth Biocare ASA
COVID-19
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
- Trial name
- NCT04377620
- Testing
- Ruxolitinib
- Where
- 36 sites in United States, Russia
- Volunteers
- 211 people
- Sponsor
- Incyte Corporation
COVID-19
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
A randomized, observer-blind, placebo-controlled immuno-bridging, and broadening study to demonstrate the equivalence of the immune response between participants enrolled in Phase 3 efficacy trial in India and demographically…
- Trial name
- NCT05258669
- Testing
- BBV152
- Where
- 10 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Ocugen
COVID-19
An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan
This is an observational, cohort study that will use secondary data to describe the baseline demographics and clinical characteristics in patients who received EVUSHELD as PrEP against SARS-CoV-2 infection/COVID-19 in Japan.
- Trial name
- Evusheld DBR (NCT06156982)
- Testing
- Evusheld
- Where
- Japan
- Volunteers
- 397 people
- Sponsor
- AstraZeneca
COVID-19, Sars-CoV2
A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
This study evaluates TL-895, a tyrosine kinase inhibitor (TKI). This is a study comprising a Phase 1 safety assessment. TL-895 open-label will be administered orally at an assigned dose continuously in 7-day cycles for 2 cycles.
- Conditions
- COVID-19, Sars-CoV2, Cancer, Solid Tumor
- Trial name
- NCT04419623
- Testing
- TL-895
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Telios Pharma, Inc.
COVID-19 SARS-CoV-2 Infection, COVID-19
A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19
The purpose of this study is to learn about how well the yearly updates to the COVID-19 vaccine work in adults (age 18 years and above) with a healthy immune system (the body's cells, tissues and organs that work together to…
- Conditions
- COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection, Coronavirus Disease 2019 (COVID-19)
- Trial name
- NCT06923137
- Testing
- BNT162b2
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Healthy
Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
The purpose of the AcRIS study is to obtain data to characterize the relationship between symptoms and voice features for (reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome…
- Trial name
- NCT04748445
- Testing
- SARS-CoV-2/Influenza/RSV RT-PCR
- Where
- United States
- Volunteers
- 9,151 people, healthy volunteers welcome
- Sponsor
- Pfizer
Post-COVID-19 Syndrome, Fatigue Syndrome, Chronic
REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID
Following acute COVID-19, some patients develop a group of debilitating symptoms that include fatigue, orthostatic intolerance, difficulty with attention and concentration (often called "brain fog"), myalgias and disrupted sleep.
- Trial name
- NCT05840237
- Testing
- Anhydrous Enol-Oxaloacetate, a "Medical Food", White Rice Flour
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Terra Biological LLC
SARS-CoV-2
Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects
Determine safety and tolerability and immungenicity of investigational vaccine ARCT-021 in healthy adult volunteers.
- Trial name
- NCT04480957
- Testing
- ARCT-021 Dose 1, ARCT-021 Dose 2, ARCT-021 Dose 3
- Where
- Singapore
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
SARS CoV 2 Infection
Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients
This is a phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and pharmacokinetics of ASC10 tablets in mild or moderate COVID-19 subjects.
- Trial name
- NCT05596045
- Testing
- ASC10
- Where
- 2 sites in United States
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.